Vactosertib in Osteosarcoma

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

5 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
This study involves a taking a study drug called vactosertib by mouth. The overall goal of this study is to find out if vactosertib is a safe and effective treatment for adolescents and adults with recurrent, refractory or progressive Osteosarcoma.

Eligibility & Criteria

IRB #:
22-020384
Official Title:
A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults
Study Phase:
Phase I
Phase II
Eligible Age Range:
14 - 24 Years
Gender:
All
Study Categories:

Visit Criteria

Participants will be given vactosertib as a tablet to swallow with water and food. Study visits will include the following assessments: blood draws, electrocardiograms, echocardiograms, pregnancy testing/birth control, genetic testing, and tissue collections (archived and fresh from tumor biopsies performed for clinical indication and for research). As a participant in the study, you will receive reimbursement for any reasonable and necessary expenses in connection with the study, such as travel and parking fees.